行情

ORGS

ORGS

Orgenesis Inc
NASDAQ

实时行情|Nasdaq Last Sale

4.800
-0.100
-2.04%
已收盘, 16:00 01/27 EST
开盘
4.900
昨收
4.900
最高
4.900
最低
4.770
成交量
8,868
成交额
--
52周最高
5.93
52周最低
2.350
市值
7,757.30万
市盈率(TTM)
-3.2611
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ORGS 新闻

  • 瑞士国家旅游局:愿与中国旅游业者共克时艰
  • 中国新闻网.21分钟前
  • 日本政府提名支持宽松的经济学家安达诚司为央行执委
  • 新浪财经.26分钟前
  • 苹果上半年拟生产8000万部iPhone 全年增产10%
  • IT之家.29分钟前
  • 巴西反垄断监管机构批准波音与巴航工业合作计划
  • 新华网.50分钟前

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

ORGS 简况

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.
展开

Webull提供Orgenesis Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。